Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of 4-isothiourea butyronitrile hydrochloride in treatment of mycobacterial infection

A technology of isothiourea-butyronitrile hydrochloride and mycobacteria, which is applied in the field of medicine, can solve the problems of rifampicin treatment fatigue, achieve the effect of solving the problem of drug resistance and inhibiting survival

Pending Publication Date: 2022-01-25
CHONGQING MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in recent years, with the emergence of drug-resistant bacteria, rifampicin treatment has become increasingly exhausted

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 4-isothiourea butyronitrile hydrochloride in treatment of mycobacterial infection
  • Application of 4-isothiourea butyronitrile hydrochloride in treatment of mycobacterial infection
  • Application of 4-isothiourea butyronitrile hydrochloride in treatment of mycobacterial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] In this embodiment, the damage of 4-isothioureidobutyronitrile hydrochloride to cells is determined by in vitro experiments, so as to delineate the safe range of medication. The specific operations are as follows:

[0033] 1. Experimental materials

[0034] Cells: RAW264.7 mouse mononuclear macrophage leukemia cells;

[0035] Reagents: dimethyl sulfoxide (DMSO), DMEM high glucose cell culture medium, fetal bovine serum, phosphate buffer saline, 4-isothioureidobutyronitrile hydrochloride powder.

[0036] 2. Experimental steps

[0037] Fetal calf serum was added to the cell culture medium, and RAW264.7 cells were seeded into 96-well cell culture plates, 1*10 per well 4 After the cells adhere to the wall, add 4-isothiourea-butyronitrile hydrochloride solution (prepared with DMSO). This experiment sets up five experimental groups, which are respectively 4-isothiourea-butyronitrile hydrochloride The concentration is 10, 20, 30, 40, 50umol / L groups, and the control group w...

Embodiment 2

[0044] The present embodiment confirms by in vitro experiments that 4-isothioureidobutyronitrile hydrochloride and its combination with rifampicin can effectively inhibit the survival of mycobacteria in macrophages. The specific operations are as follows:

[0045] 1. Experimental materials

[0046] Cells: RAW264.7 mouse mononuclear macrophage leukemia cells;

[0047] Bacteria: Mycobacterium smegmatis;

[0048] Reagents: dimethylsulfoxide (DMSO), DMEM high-glucose cell culture medium, fetal bovine serum, phosphate buffer (for washing cells before digestion and preparing cell lysate), Triton X-100 (for preparing 1 % cell lysate), Middlebrook7H9 broth base, agar powder, 4-isothiourea butyronitrile hydrochloride powder, rifampicin powder.

[0049] 2. Experimental steps

[0050] Fetal calf serum was added to the cell culture medium, and RAW264.7 cells were seeded into cell culture well plates, 1*10 per well 6 cells; after the cells adhered to the wall, add Mycobacterium smegmat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly discloses application of 4-isothiourea butyronitrile hydrochloride in treatment of mycobacterium infection. The invention finds that the compound 4-isothioureidobutyronitrile hydrochloride has new application, and the compound 4-isothioureidobutyronitrile hydrochloride can inhibit the survival of mycobacteria and effectively treat the infection of mycobacteria, namely the tuberculosis when being independently applied or combined with first-line antituberculosis drugs, so that the problem of drug resistance of the tuberculosis to the existing first-line antituberculosis drugs is solved, and new means is provided for the treatment of tuberculosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of 4-isothioureidobutyronitrile hydrochloride in the treatment of mycobacterium infection. Background technique [0002] Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb) infection. According to the latest World Health Organization estimates, about 9 million people are living with TB and about 1.5 million people die from it each year. Despite global efforts to control Mycobacterium tuberculosis infection, tuberculosis remains a major public health concern and threatens the health of people worldwide. [0003] Rifampicin is a first-line anti-tuberculosis drug used clinically. It is a broad-spectrum antibiotic drug belonging to the rifamycin family. It has a strong antibacterial effect on Mycobacterium tuberculosis and is also effective against Gram-positive or negative bacteria and viruses. . However, in recent years, with the eme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/275A61K45/06A61K31/496A61P31/06
CPCA61K31/275A61K45/06A61K31/496A61P31/06A61K2300/00Y02A50/30
Inventor 徐蕾李安龙包嘉佳赖晓霏
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com